Related Experiment Video
Updated: Jul 10, 2026
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Effect of hyperbaric oxygen therapy on LV function in CAD patients after reperfusion based on echo: a meta-analysis
Ketut Angga Aditya Putra Pramana1, Ni Gusti Ayu Made Sintya Dwi Cahyani2, Yusra Pintaningrum3
1General Practitioner North Lombok General Hospital, Tanjung, West Nusa Tenggara, Indonesia.
Insights
Hyperbaric oxygen therapy (HBOT) significantly improved left ventricular ejection fraction (LVEF) in coronary artery disease (CAD) patients post-revascularization. This meta-analysis suggests HBOT is a beneficial treatment for enhancing cardiac function in CAD patients.
Area of Science:
- Cardiology
- Hyperbaric Medicine
Background:
- Coronary artery disease (CAD) management often involves revascularization, but outcomes can be suboptimal.
- Left ventricular function is a critical determinant of prognosis in CAD patients.
- Hyperbaric oxygen therapy (HBOT) is explored as an adjunctive treatment for various conditions.
Purpose of the Study:
- To evaluate the impact of HBOT on left ventricular function in patients with CAD following revascularization.
- To synthesize existing evidence on HBOT's effects on key echocardiographic parameters in CAD.
Main Methods:
- A systematic literature search was conducted in PubMed, ScienceDirect, and Cochrane databases.
- Included studies focused on HBOT's effect on myocardial function in CAD patients.
- Meta-analyses were performed on data from three observational studies (195 participants) using Review Manager v5.4.
Main Results:
- HBOT significantly increased left ventricular ejection fraction (LVEF) by 4.16% compared to non-HBOT (MD=4.16, 95%CI 0.97 to 7.34, p=0.01).
- No statistically significant differences were found in left ventricular end-diastolic volume (LVEDV) or left ventricular end-systolic volume (LVESV) between HBOT and non-HBOT groups.
- The analysis included three observational studies with a total of 195 participants.
Conclusions:
- HBOT demonstrates a significant benefit in improving LVEF in CAD patients after revascularization.
- HBOT did not show significant effects on LVEDV or LVESV in this patient population.
- This meta-analysis supports HBOT as a potentially valuable therapeutic option for enhancing cardiac function in CAD.
Abstract:
Hyperbaric oxygen therapy (HBOT) is successfully implemented for the treatment of several disorders. HBOT is a promising treatment modality for coronary artery disease (CAD), where outcomes are frequently poor despite early revascularisation. The aim of this study is to investigate the effect of HBOT on the left ventricular function of patients with CAD after reperfusion. Electronic journal searching was performed in PubMed, ScienceDirect, and Cochrane to find studies that investigate the effect of HBOT on the myocardial function of patients with CAD. The primary outcomes were left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), and left ventricular ejection fraction (LVEF). Meta-analyses were performed on included studies and mean differences (MD) and 95% confidence intervals (CI) were estimated using Review Manager v5.4. A total of three observational studies enrolling 195 participants were included in our analysis. HBOT significantly increased LVEF by 4.16% in patients with CAD after revascularisation compared with non-HBOT (MD=4.16, 95%CI 0.97 to 7.34, p=0.01). There was no statistical significance observed in the HBOT versus non-HBOT comparison on LVEDV (MD=-1.63, 95%CI -6.52 to 3.26, p=0.51) and LVESV (MD=- 1.58, 95%CI -4.06 to 0.90, p=0.21). In general, this meta-analysis shows HBOT significantly increased LVEF in patients with CAD after revascularisation compared with non-HBOT. There were no significant changes in LVEDV and LVESV in the HBOT group and non-HBOT group.
